ClinicalTrials.gg
Not yet recruitingNCT06874738Updated Mar 13, 2025

A Real-world Clinical Study on the Treatment of Menopausal Syndrome With Liuwei Dihuang Pills

An observational study in Menopausal Syndrome, sponsored by China Academy of Chinese Medical Sciences. Not yet recruiting. Open to female participants aged 45 Years to 55 Years. Per ClinicalTrials.gov, last updated 2025-03-13.

Sponsored by China Academy of Chinese Medical Sciences · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
1,000
Ages
45 Years to 55 Years
Sex
Female
01

Study summary

To evaluate the clinical efficacy of the real-world Liuwei Dihuang pills for the treatment of female menopausal syndromes, and to provide a basis for effective, safe and rational clinical use of the drug.

Read the detailed description

In this study, the patients were divided into exposed and non-exposed groups based on whether or not they were taking Liuwei Dihuang Pills.

The patients in the non-exposed group were treated routinely, and the patients in the exposed group were treated routinely + Liuwei Dihuang Pills. The patients in the exposed group were required to take the medication according to the dosage instructions for at least 4 consecutive weeks. Combined use of drugs is allowed without interfering with the treatment plan, and the use of drugs and combined use of drugs should be recorded truthfully, including the dose, duration, frequency, and so on. The type of drugs used in combination and the corresponding daily dose, daily frequency and duration of treatment. During the course of treatment, patients in both groups were required to receive follow-up assessment once every 4 weeks. Termination of the study included death, loss of patients, or achievement of study endpoints.

02

Conditions studied

  • Menopausal Syndrome

Keywords

  • Liuwei Dihuang Pills
  • The real world
  • Efficacy
  • Clinical study
03

In context

Lead sponsor

China Academy of Chinese Medical Sciences is the lead sponsor of 62 studies on the registry; 6 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
45 Years to 55 Years
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Menopausal syndrome refers to a series of physical and psychosomatic symptoms caused by the gradual decline of ovarian function and fluctuating or decreasing levels of sex hormones before and after menopause in women.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age: 45-55 years old
  2. Patients with menopausal syndrome using Liuwei Dihuang Pills
  3. Kidney Yin Deficiency Syndrome

Exclusion criteria

Exclusion Criteria:

  1. Individuals allergic to any components of the drug or ;
  2. Individuals with other endocrine diseases;
  3. Individuals with organic lesions of the reproductive system;
  4. Individuals who have undergone bilateral oophorectomy, hysterectomy, or have ovarian dysfunction;
  5. Individuals with endometrial hyperplasia or unexplained vaginal bleeding;
  6. Individuals with malignant tumors, hematologic, or immune system diseases;
  7. Individuals with severe cardiovascular, cerebrovascular, liver, or kidney diseases (e.g., serum transaminase levels more than 1.5 times the , serum creatinine above the upper limit of normal);
  8. Individuals with psychiatric disorders or dependence on alcohol or drugs;
  9. Individuals with mental illness or communication barriers;
  10. Individuals with other conditions that, in the investigator's judgment, may reduce the likelihood of enrollment or complicate the study process are not suitable for participation in this clinical research.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colours or preservatives.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
1,000 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Liuwei Dihuang Pills

    The intervention in this cohort consisted of the Six-flavoured Dihuang Pill and the rest of the conventional treatment.

    Drug: Liuwei Dihuang pills

Interventions

  • DrugLiuwei Dihuang pills

    Conventional treatment (Hormones, selective 5-hydroxytryptamine reuptake inhibitors, etc.)+ Liu Wei Di Huang Pills

06

What researchers measure

Primary outcomes

  1. Change of Menopausal Symptoms

    The Kupperman Rating Scale is a global tool for assessing menopausal symptoms. It has 13 items covering common perimenopausal symptoms like hot flashes, sweating, paresthesia, insomnia, irritability, depression, dizziness, fatigue, arthralgia, headache, palpitations, formication, urinary infections, and sexual status. Each item is weighted and summed for a total score of 0-63. A lower score means more severe perimenopausal symptoms.The modified Kupperman Rating Scale will be used to assess menopausal symptoms. Participants will complete the questionnaire before, after treatment, and during follow-up. Researchers will calculate the total score.

    Time frame: 4 weeks

  2. Change of Hormone Levels

    Sex hormone levels are key for evaluating the endocrine status of menopausal women. In patients with menopausal syndrome, sex hormone levels show elevated Follicle-Stimulating Hormone and Luteinizing Hormone, and reduced Estradiol. High Follicle-Stimulating Hormone points to ovarian dysfunction. Changes in the Luteinizing Hormone/Follicle-Stimulating Hormone ratio may be linked to polycystic ovary syndrome, and decreased Estradiol is associated with ovarian failure.

    Time frame: 4 weeks

Secondary outcomes

  1. Change of Quality in life

    The Menopause-Specific Quality of Life Questionnaire assesses menopausal women's quality of life, covering four dimensions: vasomotor symptoms, psychosocial state, physical state, and sexual life, with 29 items in total. Each item is scored from 0 to 6, where 0 means no distress and 6 means extreme distress. The average score of items in each dimension is calculated. A higher score indicates lower quality of life in that dimension.

    Time frame: 4 weeks

  2. Change of TCM Syndrome Scores

    The TCM syndrome score sheet, designed as per TCM theory, assesses menopausal patients' TCM syndromes, covering symptoms and signs inTCM, etc.Changes in TCM syndrome scores for menopausal syndrome reflect improvement or worsening. The scale uses a semi - quantitative grading method, assigning scores of 0, 1, 2, or 3 to represent the severity of symptoms in menopausal syndrome patients. The scores are added up to form the total syndrome score, with a minimum of 0 and a maximum of 42. A higher score means a more serious condition.

    Time frame: 4 weeks

07

Study locations

No study locations are listed for this record.

08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 13, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06874738
Lead sponsor
China Academy of Chinese Medical Sciences
Collaborators
Lanxi Hospital of Traditional Chinese Medicine, First Affiliated Hospital of Harbin Medical University
Responsible party
Lianxin Wang (Principal Investigator, China Academy of Chinese Medical Sciences) — Principal investigator
First posted
Mar 13, 2025
Start date
Mar 8, 2025 (estimated)
Primary completion
Dec 30, 2026 (estimated)
Completion
Dec 30, 2026 (estimated)
Last update
Mar 13, 2025

Study contacts

Lianxin Wang
Contact
wlxing2022@163.com
86-13521781839
Shichu Zhao
Contact
18513049612@163.com
86-18513049612
Lianxin Wang
principal investigator · Institute of Basic Research in Clinical Medicine, China Academy of Chinese

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion